NCT01104220View on ClinicalTrials.gov

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

NAActive, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Non-alcoholic Fatty Liver DiseaseMetabolic SyndromeMetabolically Abnormal ObesityMetabolically Normal ObesityObesity
Interventions
OTHER

Weight loss

Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01104220 - Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk | Biotech Hunter | Biotech Hunter